function getval(val){
 var a1=val.replace(/<\/?.+?>/g,"");
 var a2=a1.replace(/ /g,"");
 return a2;
}
//document.write('http://wxzl.cogonline.com/html/CeShiZhuanLanYi/ShiBin/ZhiNaWenXian/920.html');
wx.config({
debug:  false, 
appId: 'wx85d01b1d7184c45d',
timestamp: 1716290399,
nonceStr: '9km8yCWRUXATKGzC',
signature: '1e53d21f3c4c235341939842ea55f01c89dfc947',
jsApiList: [ 
   'checkJsApi', 
   'onMenuShareTimeline', 
   'onMenuShareAppMessage', 
   'onMenuShareQQ', 
   'onMenuShareWeibo'
]
});
wx.ready(function () { 
	wx.onMenuShareTimeline({  
	title: '尼拉帕利个案荟萃系列②｜一文梳理难治肿瘤新探索', 
	link: 'http://wxzl.cogonline.com/html/CeShiZhuanLanYi/ShiBin/ZhiNaWenXian/920.html',
	imgUrl: 'http://wxzl.cogonline.com/wp/logo.jpg',
	success: function () {
		//alert('fx-ok');
	},
	cancel: function () {
		//alert('fx-no');
	}
	});
	wx.onMenuShareAppMessage({  
		title: '尼拉帕利个案荟萃系列②｜一文梳理难治肿瘤新探索', 
		link: 'http://wxzl.cogonline.com/html/CeShiZhuanLanYi/ShiBin/ZhiNaWenXian/920.html',
		imgUrl: 'http://wxzl.cogonline.com/wp/logo.jpg',
		desc: getval('PARP抑制剂已经是晚期卵巢癌维持治疗的基石，尼拉帕利作为“强”PARPi，唯一单药获批新诊断晚期卵巢癌全人群的维持治疗适应症，对于一些HRD通路异常的非卵巢癌、难治性肿瘤能否续写辉煌呢？本期文献精读特别邀请来扬州大学附属医院的薛金俊医生，解读近几年尼拉帕利在其他瘤种中成功治疗的个案报道。             00:000:00              '),
		success: function () {
			//alert('fx-ok');
		},
		cancel: function () {
			//alert('fx-no');
		}
	});
});	
wx.error(function (res) {
	//alert(location.href.split('#')[0]);
	//alert('err:'+res.errMsg);  
});
if(location.href.indexOf("?") >= 1 ){
	location.href=location.href.substring(0,location.href.indexOf("?"));
}